|
1
|
54 F
|
Anti-CLA-4, interferon (IFN)
|
M1c: Mesentery, small bowel, lymph nodes (LN)
|
PR
|
8
|
|
2
|
34 F
|
Anti-PD1, anti-CLA-4, IFN, IL-2 + radiation (XRT), temozolomide
|
M1c: Brain, kidneys, adrenals, bone, liver, LN, subcutaneous (SC)
|
SD
|
3
|
|
3
|
61 M
|
IL-2, BRAF inhibitor
|
M1c: Brain, liver, lungs, SC, mesentery, chest wall
|
PD (Progression in brain, but PR in extracranial sites)
|
8, for extracranial response
|
|
4
|
27 F
|
IL-2, anti-CTLA-4+IL-21, anti-CTLA-4 + XRT, recombinant IL-15
|
M1c: Brain, SC, LN, pleura, kidneys, peritoneum
|
SD
|
3
|
|
5
|
63 M
|
Anti-CTLA-4
|
M1a: Intramuscular, LN
|
CR
|
17, ongoing
|
|
6
|
52 M
|
Anti-CTLA-4
|
M1a: SC, LN
|
CR
|
20, ongoing
|
|
7
|
31 F
|
Anti-PD1, anti-CTLA-4, decarbazine, BRAF/MEK inhibitor
|
M1c: Brain, lungs, liver, SC
|
SD
|
5
|
